Ackers Ian S, Witzke Jacquelyn A, Saremi Arvin, Farley Tyler K, Thompson Nicolas R, Li Yadi, Foresi Brian D, Goyal Kush K
Physical Medicine and Rehabilitation, Michigan State University, East Lansing, USA.
Physical Medicine and Rehabilitation, Mary Free Bed Rehabilitation Hospital, Grand Rapids, USA.
Cureus. 2025 Mar 3;17(3):e79962. doi: 10.7759/cureus.79962. eCollection 2025 Mar.
Chronic low back pain is a prevalent condition that is treated commonly with radiofrequency neurotomy (RFN) after diagnostic targeting with medial branch blocks (MBB) or intra-articular (IA) injection.
We evaluated the long-term therapeutic value of MBB and IA injection of steroids for relief from chronic low back pain beyond the current diagnostic utility.
This was a retrospective propensity-matched cohort study from a single physician injection census at a tertiary care hospital. A total of 460 patients receiving MBB (n=383) or IA injection (n=77) in 2013-2020 were included. Primary outcome measures were patient-reported outcomes (PROs) at the time of injection, and follow-up at three and six months with the Numerical Rating Scale (NRS), PRO Measurement Information System (PROMIS)-Mental Health (MH), PROMIS-Physical Health (PH), and the Patient Health Questionnaire (PHQ)-9 scores. The same PROs at the one-year follow-up were the secondary outcome measures. Propensity weighting was performed to balance MBB and IA injection groups over several demographic and clinical categories.
Significant improvements in NRS (p=<0.001) were reported at the three-month, six-month, and one-year follow-ups, while significant improvements in PROMIS-PH scores (p=0.015) were identified at three and six months post injection.
Our results suggest that MBB and IA injection have potential therapeutic benefits for chronic low back pain for at least six months post injection. These results suggest that there is value in these diagnostic modalities therapeutically beyond the acute time frame. These results lay the groundwork for additional investigations into treatment options for patients affected by chronic low back pain.
慢性下腰痛是一种常见病症,通常在内侧支阻滞(MBB)或关节内(IA)注射进行诊断性定位后,采用射频神经切断术(RFN)进行治疗。
我们评估了MBB和IA注射类固醇对缓解慢性下腰痛的长期治疗价值,其作用超出了当前的诊断效用。
这是一项回顾性倾向匹配队列研究,来自一家三级护理医院的单一医生注射普查。纳入了2013年至2020年期间接受MBB(n = 383)或IA注射(n = 77)的460例患者。主要结果测量指标为注射时患者报告的结果(PROs),以及在三个月和六个月随访时使用数字评定量表(NRS)以及PRO测量信息系统(PROMIS)-心理健康(MH)、PROMIS-身体健康(PH)和患者健康问卷(PHQ)-9评分进行的随访。一年随访时相同的PROs为次要结果测量指标。进行倾向加权以平衡MBB和IA注射组在几个人口统计学和临床类别方面的差异。
在三个月、六个月和一年随访时报告NRS有显著改善(p =<0.001),而在注射后三个月和六个月时发现PROMIS-PH评分有显著改善(p = 0.015)。
我们的结果表明,MBB和IA注射对慢性下腰痛在注射后至少六个月具有潜在治疗益处。这些结果表明,这些诊断方式在治疗方面的价值超出了急性时间段。这些结果为进一步研究慢性下腰痛患者的治疗选择奠定了基础。